Clinical Trials
12 trialsNCT02780700 2025-02-03
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Boehringer Ingelheim
Phase 2 Terminated
NCT02902484 2024-06-03
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT03287947 2022-08-09
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Wake Forest University Health Sciences
Phase 2 Terminated
NCT02393755 2021-07-08
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT02234596 2021-01-25
Nintedanib in Patients With Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01362361 2019-09-19
AIO-KRK-0111
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Completed
NCT00801294 2017-12-29
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01004003 2017-10-26
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 2 Completed
NCT02149108 2017-07-21
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Boehringer Ingelheim
Phase 3 Completed
NCT00987935 2016-03-10
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Boehringer Ingelheim
Phase 2 Completed
NCT01594125 2016-02-12
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 1 Completed
NCT00904839 2015-02-04
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed